The U.S. Food and Drug Administration (FDA) approved the use of ivacaftor (Kalydeco®) today for people ages 2 and older with cystic fibrosis who have at least one of the following five splice mutations: 3849+10kbC->T, 2789+5G->A, 3272-26A->G, 711+3A->G, E831X.
Site Search
The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Bill Would Remove Financial Penalties for Participating in Research Studies
CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality
Kids from 20 States Make Case for Drug Funding and Access to Care for Fatal Disease
New Effort Will Search for Potential Therapies Targeting the Most Common Mutation of Cystic Fibrosis
Legislation Would Increase Patient and Expert Participation in FDA Review of Rare Disease Treatments
Legislation Would Increase Patient and Expert Participation in FDA Review of Rare Disease Treatments